Last updated on November 2019

Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer


Brief description of study

This study will enroll subjects with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A subjects will receive BGB-290; in Arm B subjects will receive placebo. The purpose of this study is to show that BGB-290 (versus placebo) will improve progression-free survival (PFS) in subjects with advanced or inoperable gastric cancer.

Detailed Study Description

This is a double-blind, placebo controlled, randomized multicenter global phase 3 study comparing the efficacy and safety of single agent poly (ADP-ribose) polymerase (PARP) inhibitor BGB-290 to placebo as maintenance therapy in subjects with advanced gastric cancer who have responded to first line platinum based chemotherapy. Subjects are randomized 1:1 to BGB-290 (Arm A) or placebo (Arm B). Randomization will be stratified by geography, biomarker status, and ECOG performance status.

Patients will undergo tumor assessments at screening and then every 8 weeks, or as clinically indicated. Administration of BGB-290 or placebo will continue until disease progression, unacceptable toxicity, death, or another discontinuation criterion is met.

After end of treatment, long-term follow-up assessments include tumor imaging every 8 weeks for those patients without disease progression, survival status, and new anticancer therapy.

Clinical Study Identifier: NCT03427814

Find a site near you

Start Over

St Joseph Heritage Healthcare

Santa Rosa, CA United States
  Connect »

Cancer Center of Kansas

Wichita, KS United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

Stephenson Cancer Center - Oncology

Oklahoma City, OK United States
  Connect »

Renovatio Clincal

The Woodlands, TX United States
  Connect »

Monash Health

Clayton, Australia
  Connect »

UZ Antwerpen

Wilrijk, Belgium
  Connect »

UZ Gent

Gent, Belgium
  Connect »

ICM Val d'Aurelle

Montpellier Cedex 5, France
  Connect »

ICO

Angers Cedex 2, France
  Connect »

Queen Mary Hospital

Hong Kong, Hong Kong
  Connect »

Raffles Hospital

Singapore, Singapore
  Connect »

Institut Catal d Oncolog a (I.C.O.)

L'Hospitalet de Llobregat, Spain
  Connect »

Mount Vernon Hospital

Northwood, United Kingdom
  Connect »